Ambulatory Oxygen Therapy for COPD

This trial aims to determine whether people with fibrotic interstitial lung disease (ILD) or chronic obstructive pulmonary disease (COPD) benefit more from different types of oxygen equipment during activity. Participants will try two options: traditional oxygen tanks and portable oxygen concentrators (POCs), compared to no oxygen therapy, to identify which improves symptoms and quality of life. The trial seeks individuals with these lung conditions who experience low oxygen levels only during activities like walking or exercising, without using a cane or walker. As an unphased trial, it offers participants the chance to contribute to valuable research that could enhance treatment options for others with similar conditions.

The trial does not specify if you need to stop your current medications, but it requires that your lung disease has been stable on the same medical therapy for the past 3 months.

Studies have shown that using oxygen therapy while moving around, known as ambulatory oxygen therapy (AOT), is generally safe for people with long-term lung diseases like COPD (chronic obstructive pulmonary disease) and ILD (interstitial lung disease). Research has indicated that long-term oxygen use can reduce the risk of serious health problems and even death in COPD patients, suggesting that oxygen therapy can be well-tolerated over time.

However, not everyone experiences the same benefits. Some studies found that portable oxygen treatments might not improve symptoms for all COPD patients with moderately low oxygen levels. This indicates that while AOT is safe, its effectiveness can vary from person to person.

In terms of safety, using devices like portable oxygen tanks or concentrators is considered low-risk. People using these devices typically do not report serious side effects. The main challenge might be adjusting to the equipment, rather than any direct harm from the therapy itself.

Researchers are excited about ambulatory oxygen therapy for COPD because it offers mobility and convenience that traditional oxygen therapy often lacks. Unlike stationary oxygen setups, portable compressed oxygen D-tanks and portable oxygen concentrators allow patients to move freely outside their homes while receiving treatment. This mobility is particularly beneficial for COPD patients who experience exertional hypoxemia, as it enables them to maintain an active lifestyle and improves their overall quality of life. Additionally, these portable systems could provide a more consistent oxygen supply during physical activity, potentially leading to better management of symptoms and improved exercise tolerance.

This trial will compare the effects of ambulatory oxygen therapy in participants with chronic obstructive pulmonary disease (COPD) and those with fibrotic interstitial lung disease (ILD). Studies have shown that long-term oxygen therapy can reduce the risk of death and illness in people with COPD. Some research suggests that portable oxygen can help those with severe COPD become more active by easing movement. However, recent findings indicate that portable oxygen might not benefit everyone, particularly those with only moderately low oxygen levels. Current guidelines recommend maintaining oxygen levels between 88–92% to prevent issues like low oxygen (hypoxia) or excessive oxygen (hyperoxia). While using oxygen on the go shows promise, more research is needed to confirm its benefits during everyday activities for people with COPD and ILD.¹³⁴⁵⁶